Nice to be on the money honey!
This is a further validation of the potential of the Progenza platform.
I think the imminent pain study report will critical in expanding the areas in which Progenza can be applied.
As said before, AGC must be happy, and will have every incentive use its substantial name, contacts, expertise to get the phase 2 trial partner for Japan and get the ball rolling.
Thee next milestone payment? A phase 2 partner named? ...in addition to further upfront/milestones from the pharma partner
RGS Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
